Heisoog Kim1,2, Ciprian Catana1, Eva-Maria Ratai1, Wei-Ting Zhang1, Ovidiu C. Andronesi1, Tracy T. Batcheolor3, Rakesh K. Jain4, Alma Gregory Sorensen1
1A.A.Martinos center, Massachusetts General Hospital, Charlestown, MA, United States; 2NSE/HST, Massachusetts Institute of Technology, Cambridge, MA, United States; 3Neurology, Massachusetts General Hospital, Boston, MA, United States; 4Radiology, Massachusetts General Hospital, Boston, MA, United States
This study investigated early changes in predominant metabolites for assessment of tumor response to anti-angiogenic agents in rGBM using 1H-MRS. After one dose, NAA/norCre in ET showed a significant increase in good-OS patients (12/19) and no such increase in poor-OS. NAA/Cho increased in good-OS, while decreasing in poor-OS. There were no significant changes in norCre or MRI parameters, including T1, FLAIR, and ADC. The change in NAA/norCre after one dose suggests a revival of neuronal activity as well as a recovery of metabolite concentrations due to reduction of edema. NAA/Cho changes also seem to correlate well with overall survival.